UROCIT-K DIN 01914022
Status: Cancelled Post Market
Holder: MISSION PHARMACAL COMPANY
Molecule: POTASSIUM CITRATE
Available to quote
Health Canada record
| Active ingredient(s) | POTASSIUM CITRATE 540 MG |
|---|---|
| Dosage form | Tablet (Extended-Release) |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | A12BA02 POTASSIUM CITRATE |
| Original market date | 01-Jan-1995 |
| Current status date | 17-Sep-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Mission Pharmacal Company — licence , not currently licensed, last inspection rating C (2022-09-19).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing POTASSIUM CITRATE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02353997 | UROCIT-K | MISSION PHARMACAL COMPANY | Tablet (Extended-Release) | POTASSIUM CITRATE 1080 MG | Marketed |
International API supply for POTASSIUM CITRATE
1 valid EDQM Certificates of Suitability from 1 holders. 7 active FDA Drug Master Files.
Request a quote for UROCIT-K